Fintel reports that on April 9, 2025, Guggenheim initiated coverage of Elevance Health (NYSE:ELV) with a Buy recommendation.

Over 90,000 patients face difficult decisions after Anthem Blue Cross Blue Shield and MU Health Care didn't reach a deal.

Shares of Apple and Tesla have lost more than 10% since “Liberation Day” during the stock market rollercoaster.

Ekirch said specialists have suggested that a series of infusions made from blood plasma called intravenous immunoglobulin — ...

Find out in our full research report, it’s free. Formerly known as Anthem until its 2022 rebranding, Elevance Health (NYSE:ELV) is one of America's largest health insurers, serving approximately ...

In its first quarter 2025 investor letter, GreensKeeper Asset Management emphasized stocks such as Elevance Health, Inc. (NYSE:ELV). Elevance Health, Inc. (NYSE:ELV) is a health benefits company ...

Indianapolis-based health Elevance Health’s board is recommending its investors reject a shareholder proposal that asks the ...

Truist raised the firm’s price target on Elevance Health (ELV) to $510 from $480 and keeps a Buy rating on the shares as part of a broader ...

Guggenheim initiated coverage of Elevance Health (ELV) with a Buy rating and $518 price target The firm launched coverage on 11 healthcare ...

With a market cap of $102.5 billion, Elevance Health, Inc. (ELV ... and healthcare management services under brands such as Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon.

Shares of Elevance Health, Inc. (NYSE:ELV – Get Free Report) have been given a consensus rating of “Moderate Buy” by the ...